Retatrutide is an investigational multi-receptor peptide agonist that combines activity at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is a next-generation metabolic therapy designed to leverage the synergistic effects of these three hormonal pathways to improve energy expenditure, insulin sensitivity, and appetite control.
Mechanistically, GLP-1 and GIP agonism enhances glucose-dependent insulin secretion, delays gastric emptying, and reduces food intake, while glucagon receptor activation increases lipolysis and energy expenditure. This triple-action design has shown promising results in early research models and clinical trials for inducing sustained weight loss, improving glycemic control, and optimizing lipid metabolism.
Retatrutide represents a new class of metabolic modulators aimed at addressing complex conditions such as type 2 diabetes, obesity, and metabolic syndrome. Current studies are exploring its long-term effects on body composition, cardiometabolic markers, and hepatic fat reduction, positioning it as a potential comprehensive therapeutic strategy for metabolic disorders.
